Physician profile
Sunil Natrajan
NPI 1831181189
$5,325.29
in general payments reported to CMS, 2019-2025
24 companies · $125 in 2025
The $125 reported for 2025 was less than what a typical Pulmonary Disease provider received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,315 · 2020: $653 · 2021: $1,135 · 2022: $896 · 2023: $201 · 2025: $125.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $326.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $325.60 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $1,714.54 | 2019-2023 | Trelegy Ellipta |
| Astrazeneca Pharmaceuticals LP | $688.33 | 2019-2025 | Tezspire |
| Philips North America LLC | $379.12 | 2019-2021 | |
| Insmed, INC. | $351.97 | 2019-2023 | Arikayce |
| Actelion Pharmaceuticals US, INC. | $289.65 | 2021-2023 | Uptravi, Opsumit |
| Genzyme Corporation | $246.75 | 2019-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $225.24 | 2019-2022 | |
| Genentech USA, INC. | $181.60 | 2019-2022 | |
| Medtronic, INC. | $181.44 | 2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $144.51 | 2022 | |
| Amgen INC. | $136.17 | 2021-2022 | |
| Electromed, INC. | $135.47 | 2019-2022 | |
| Grifols USA, LLC | $134.13 | 2019-2022 | |
| Regeneron Healthcare Solutions, INC. | $95.39 | 2019-2020 | |
| Jazz Pharmaceuticals INC. | $94.40 | 2019-2022 |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Intuitive Surgical, INC. | $89.69 | 2023 | Da Vinci Surgical System |
| Mylan Specialty L.P. | $54.30 | 2019-2023 | Yupelri |
| Sunovion Pharmaceuticals INC. | $45.32 | 2019 | |
| Acacia Pharma INC | $41.47 | 2021-2022 | |
| Pulmonx Corporation | $25.16 | 2019 | |
| Pari Respiratory Equipment, INC. | $22.11 | 2019 | |
| Teva Pharmaceuticals USA, INC. | $17.86 | 2020 | |
| United Therapeutics Corporation | $17.73 | 2022 | |
| Apria Healthcare LLC | $12.94 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sunil Natrajan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.